A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Obesity is a chronic, multifactorial metabolic disease associated with various factors such as insulin resistance, increased adipogenesis, induction of gluconeogenesis, epigenetic mechanisms, chronic inflammatory state, and oxidative stress. Anti-obe…
The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigationa…
BACKGROUND: Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes. This review synthesizes current evidence on pharmac…
Obstructive sleep apnea (OSA) is a breathing disorder characterized by repeated, com-plete, and partial upper airway blockage, which results in disturbances in sleep patterns, neurocog-nitive functions, and hypoxemia. It is strongly linked to obesity…
RATIONALE: Obesity is a complex chronic condition linked to various comorbidities, such as hypertension, diabetes, and dyslipidaemia, with a significant global burden. Standard treatments, such as diet, exercise and behavioural changes, often have li…
BACKGROUND: Emotional reactions to treatment could affect treatment adherence and treatment outcomes, and it is therefore important to assess the emotional impact of treatment and consider this impact in clinical decision-making. The Emotional Impact…
OBJECTIVE: This study aimed to determine whether weight reduction mediated by antiobesity medications (AOMs) contributes to the risk reduction in obesity-associated cancer. METHODS: PubMed, Embase, the Cochrane Central Register of Controlled Trials,…
This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications…
BACKGROUND: Incretin mimetics, especially dual/triple agonists, are effective for type 2 diabetes and obesity, though mechanisms remain unclear. This study applied PET using [Ga]Ga-DO3A-Exendin-4 and [Ga]S02-GIP-T4 to assess GLP-1R and GIPR occupancy…